![]() Specifically, cell-based therapies for liver cirrhosis have successfully progressed from preliminary laboratory and pre-clinical evaluations. Stem cell therapy has emerged as an attractive therapeutic approach for a myriad of life-threatening diseases in recent years. These limitations have driven researchers and clinicians to develop novel therapeutic strategies to reduce the morbidity and mortality burden of the disease. However, the efficacy and widespread application of OLT is hampered by the shortage of matching donors, surgery-associated morbidities and risk of graft-rejection. OLT for liver cirrhosis result in a 5-year survival rate of about 70%. At present the only effective therapeutic option is Orthotopic Liver Transplantation (OLT). Unfortunately various therapeutic-associated limitations have led to the increase in fatality rates over the years. The treatment of cirrhosis is designed to hinder further liver damage, treat cirrhotic complications and prevent liver cancer. ![]() As a result, liver cirrhosis accounts for more than one million worldwide deaths annually and an even greater disease-associated morbidity burden. Besides reduced quality of life, individuals with liver cirrhosis also have an increased risk of liver cancer. In addition, liver cirrhosis is also characterized by the formation of regenerative nodules that eventually replace the entire liver architecture, leading to decreased blood flow throughout the liver. It is usually characterized by hepatocyte necrosis, defenestration, collagen deposition contributes to fibrosis that ultimately lead to the cumulative loss of liver function. Many chemicals, viruses and toxic substances have been associated with the development of cirrhosis. Liver cirrhosis is an end-stage pathological condition that results from a range of chronic liver diseases. Thus, this article attempts to review and consolidate the various cellular source, type, dose, and mode of delivery permutations across the various clinical studies published to date. Many variations exist across the different clinical studies conducted and this hampers the mainstream clinical realization of adult stem cell-based therapy for liver cirrhosis. However, there is still a lack of consensus with regards to the optimum standardization of stem cell source, type, dosage, and mode of transplantation. Autologous and allogeneic adult stem cell-based therapies have shown promising results in restoring liver function in cirrhosis patients. Although both of these cells have in vivo ability to generate hepatocytes-like cells, MSCs are more potent. The bone marrow serves as an ideal source of Hematopoietic Stem Cells (HSCs) and Mesenchymal Stem Cells (MSCs). ![]() Since adult stem cells can be effectively differentiated into hepatocyte-like cells, the potential to translate this utility as a therapeutic alternative has been considerably explored. The shortage of matching donors and the high risk of surgical-associated complications further limits the therapeutic potential of transplantation. Although treatable by liver transplantation, quality of life is unlikely to drop in all the patients after five years. Liver cirrhosis is a leading cause of mortality worldwide. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Baskar Subramani, Nichi-Asia Life Science Sdn Bhd, (786331-D) 57, Block F, Jalan Teknology 3/9 Bistari "De" Kota, Kota Damansara PJU 5, 47810 Petaling Jaya Selangor Darul Eshan, Malaysia, Tel: +603-6142-1920/21, Fax: +603-6142.Ĭitation: Gounder SS, Kodiappan R, Chan SC, Veerakumarasivam A, Subramani B (2017) Adult Stem Cell Therapy in Liver Cirrhosis Management: Current Practices and Future Perspectives. Sellamuthu Subbanna Gounder 1, Radha Kodiappan 2, Soon Choy Chan 3, Abhi Veerakumarasivam 4 and Baskar Subramani 1*ġNichi-Asia Life Science Sdn Bhd, Selangor, MalaysiaĢPerdana University Royal College of Surgeon Ireland, Perdana University, 43400 Serdang, Selangor Darul Ehsan, MalaysiaģPerdana University School of Foundation Studies (PUSFS), Perdana University, 43400 Serdang, Selangor Darul Ehsan, MalaysiaĤSunway Institute for Healthcare Development, Sunway University, Bandar Sunway, 47500 Subang Jaya, Selangor Darul Ehsan, Malaysiaĭr. REVIEW ARTICLE | VOLUME 4, ISSUE 2 | OPEN ACCESS DOI: 10.23937/2469-570X/1410049Īdult Stem Cell Therapy in Liver Cirrhosis Management: Current Practices and Future Perspectives ![]()
0 Comments
Leave a Reply. |